Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Mitapivat, sold under the brand name Pyrukynd among others, is a medication used to treat different types of anemia. It is taken as the sulfate hydrate salt by mouth. Mitapivat is a pyruvate kinase activator.
Community, Culture, Applications & Products
Explore the main themes, entities and connections around Mitapivat. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
pyruvate kinase trial deficiency pyrukynd us salt blood participants approved medical medication ag-348 activator drug administration anemia names treatment brand
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Mitapivat | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Mitapivat | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Mitapivat | ATC code | B06AX04 (WHO) | 1.00 | infobox |
| Mitapivat | CAS Number | 1260075-17-9 | 1.00 | infobox |
| Mitapivat | ChEMBL | ChEMBL4299940 | 1.00 | infobox |
| Mitapivat | ChEMBL | as salt: ChEMBL4297223 | 1.00 | infobox |
| Mitapivat | ChemSpider | 29763395 | 1.00 | infobox |
| Mitapivat | Drug class | Pyruvate kinase activator | 1.00 | infobox |
| Mitapivat | DrugBank | DB16236 | 1.00 | infobox |
| Mitapivat | DrugBank | as salt: DBSALT003215 | 1.00 | infobox |
| Mitapivat | Formula | C24H26N4O3S | 1.00 | infobox |
| Mitapivat | IUPHAR/BPS | 10473 | 1.00 | infobox |
| Mitapivat | KEGG | as salt: D11408 | 1.00 | infobox |
| Mitapivat | Legal status | US: ℞-only | 1.00 | infobox |
| Mitapivat | Legal status | EU: Rx-only | 1.00 | infobox |
| Mitapivat | License data | US DailyMed: Mitapivat | 1.00 | infobox |
| Mitapivat | MedlinePlus | a622018 | 1.00 | infobox |
| Mitapivat | Molar mass | 450.56 g·mol−1 | 1.00 | infobox |
| Mitapivat | Other names | AG-348, Mitapivat sulfate (USAN US) | 1.00 | infobox |
| Mitapivat | PubChem CID | 59634741 | 1.00 | infobox |
| Mitapivat | Routes of administration | By mouth | 1.00 | infobox |
| Mitapivat | Trade names | Pyrukynd | 1.00 | infobox |
| Mitapivat | UNII | 2WTV10SIKH | 1.00 | infobox |
| Mitapivat | UNII | as salt: N4JTA67V3O | 1.00 | infobox |
| Mitapivat | is a | pyruvate kinase activator.The most common side effects include decreases in estrone and estradiol | 0.90 | text |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.